First, NOD1 agonist TriDAP reduced the SARS-CoV-2-GFP+ cells by 49% (p < 0.01), whilst dual NOD1/2 ligand M-TriDAP reached up to 57% of infection inhibition (p < 0.01), compared to the untreated control. This evidence concerns the gene NOD1 and infection.